HU-6 is a CMA, administered orally once a day, currently under development for the treatment of obesity and related complications, such as T2DM, MASH, severe hypertriglyceridemia, and heart failure with preserved ejection fraction (HFpEF) ( The HuMAIN study, a phase 2a trial examining HU-6 in subjects with HFpEF shows a mean weight loss of 3.1kg compared to 0.2 kg for the placebo group at three months ( 7 Melanocortin 4 receptor agonists 7.1 Setmelanotide Setmelanotide is a melanocortin-4 receptor (MC4R) agonist that is administered subcutaneously once a day ( It is being investigated for treatment of various heterozygous mutations in LepR, POMC, or PCSK1 genes, and homozygous or heterozygous mutations in the steroid receptor coactivator-1 (SRC1) or SH2B adapter protein 1 (SH2B1) genes ( Setmelanotide is currently being studied for treatment of acquired hypothalamic obesity (HO), a condition occurring after injury to the relevant satiety centers, also characterized by hyperphagia and rapid weight gain
Kiser, P
Injection site reactions including pain, swelling, or redness
This pattern allows any potential receptor adaptation to normalize while preventing dependence on the peptide for sleep
Other longevity strategies possess more robust human data : Proven methods, including NMN and resveratrol strategies or Mediterranean Diet 3.0 protocols, rely on multiple human trials and biomarker analyses
Mago, T
